P2-136: Discrepancy of Lung Cancer Cell Growth in Bone Microenvironments
Jie Zhang,Mei-Lin Liao,Yi Zhao,Hai-Quan Chen,Jia-Qing Xiang,Qiang Tan,Shun Lu
DOI: https://doi.org/10.1097/01.jto.0000283600.70856.12
IF: 20.121
2007-01-01
Journal of Thoracic Oncology
Abstract:Disseminated cancer cells may initially require local nutrients and growth factors to thrive and survive in bone marrow before developing into overt metastasis. Bone seems a milieu particularly favorable for the growth, vascularization and survival of lung cancer. In order to explore the mechanism how bone stromal factors contribute to the bone tropism, we therefore use serum of bone marrow aspiration (BM) and condition medium from bone stromal cells(BSC) to study their effects on lung cancer cells. Lung cancer cell lines, A549, H460, gastric cancer cell line SGC-7901 were obtained originally from ATCC. SPC-A1 lung cancer cell line, tong cancer cell line T8113 and primary bone stromal cells were established in our lab before, and reported in many publications. These cells were cultured in pheno- red -free DMEM / 10% fetal calf serum. Regular medium(RM), condition medium from fibroblast cell(FC) were chosen as controls. MTT assay was applied to analyze these different treatments on proliferation of lung cancer cells and controls. Flow cytometry analysis of DNA content was performed to assess the cell cycle phase distribution using propidium iodide fluorescence. Adhesion assay was used to compare cells adhesion on the plates coated with different medium. (1) In our cancer center, disseminated cancer cells were found in 35% lung cancer patients, 41.7% breast cancer patients, and 39.6% gastric cancer patients. Bone metastasis was often in breast/lung cancer patients, but very rare in gastrointestinal cancer patients. (2) Both supernatants from BM and BSC significantly increased the proliferation of H460 lung cancer cells, which had widespread skeletal metastatic potential Yang M, Cancer Res. 1998). This activity was not shown in A549 and SPC-A1 lung caner cells, which had low bone metastasis potential according to literal reports and our animal study. BM did not improve the proliferation of tong cancer cells T8113, which had very low bone metastasis potential, and even inhibited the growth of SGC7901 gastric cancer cells. (3) Bone- stromal- cell- induced proliferation in H460 cells was blocked by Zometa (biphosphanate), but not by PI3-K inhibitor Wartmannin in time-course and doze dependent studies. (4)BM and BSC also induced cell cycle progression in H460 cells, but not A549 and SPC-A1 cells shown by flow cytometry. (5) Some factors literally related to bone metastasis were compared. ELISA showed the levels of TGF-b, HGF, IGF-1, IL-6 and PDGF were identical in BM, BSC, RM and FC. (6) Similar numbers of H460 cells adhered to BM, BSC and RM coated plates. There were also no significant difference for SPC-A1 and A549 cells in adhesion capability to different medium. Although a supporting role of bone stromal factors on metastatic breast or prostate cancer cells have been repeatedly proposed, it is largely unknown the mechanism of bone tropism for lung cancer. In our study, we found bone stromal factors favored the growth of cancer cells with bone tropism by increasing proliferation, cell cycle progression, but not adhesion capability. Bone stromal cells should secret some growth factors although not identified by ELISA, which promoted the proliferation of high bone metastasis potential cells. The high through-out assay, 2D gel followed by mass spectromics, is currently ongoing to recognize the effective factors.